Company Profile
Quan Capital is a healthcare-focused global venture capital firm that identifies, incubates, and grows next-generation life sciences companies. The firm's investment philosophy is centered on discovering disruptive solutions to critical healthcare problems that impact millions of lives. They invest in innovative early and growth-stage companies globally and in China, with a specific focus on therapeutic biotech/pharma, enabling technologies/high-end specialty services, and companion diagnostics & precision medicine.
Founded in 2017, Quan Capital was established with a mandate to incubate and develop life sciences companies. The firm's founding managing director is Samantha Du, known for her role in establishing Zai Lab, a US-listed Chinese drug developer. Other managing directors include Marietta Wu and Stella Xu, both bringing extensive experience from the pharmaceutical and biotech industries.
The firm's portfolio includes a diverse range of companies in the life sciences sector. Notable investments and portfolio companies mentioned include Alebund Pharmaceuticals, Tempest, Arcellx (acquired by Gilead Sciences), Avenzo Therapeutics, Windward Bio, Adcentrx Therapeutics, OriCell Therapeutics, Qiagen, Design Therapeutics, Interius Biotherapeutics, Adicet Bio, NextCure, Zenas BioPharma, Syros Pharmaceuticals, ICarbonX, Kira Pharmaceuticals, MEDx, Yuanyin Bio, Silexon, Therorna, Zidan, ARMO BioSciences, and dMed.
Quan Capital emphasizes providing "smart capital" by leveraging its broad scientific knowledge, cross-functional operational experiences, deep company-building leadership guidance, and an extensive global and local network. The investment professionals, empowered by strong expertise in both science and business, are deeply involved in company building, supporting strategy, operation, and development to maximize company value across different development stages and geographies.
News & Signals (0)
No linked news activity found for this company.